Идёт набор NCT07447440

Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases

— Наблюдательное Breast Cancer Health, Subjective Obesity

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Observational study (baseline), Observational study (baseline and 1 year).
Кому может быть актуально: Состояния в реестре: Breast Cancer, Health, Subjective, Obesity. Базовые параметры: Без ограничений · Женщины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Испания
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Unraveling the Role of Pro-Resolving Lipid Mediators of Inflammation and Their Receptors in Obesity-Associated Diseases: New Therapeutic Approaches for Maresin 1 (RESOLBE)

Обзор

The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight/obesity. Specific objectives are: * To analyse anthropometric and body composition changes. * To evaluate physical activity level. * To determine dietary profile. * To determine the adherence to Mediterranean dietary pattern. * To assess the quality of life. * To determine levels of specialized pro-resolving lipid mediators The target sample size is 60 subjects. Participants will be allocated in four groups: * Group 1: Postmenopausal healthy women with overweight/obesity (n=15) * Group 2: Postmenopausal healthy women with normoweight (n=15) * Group 3: Postmenopausal women with breast cancer and overweight/obesity (n=15) * Group 4: Postmenopausal women with breast cancer and normoweight (n=15)

Подробное описание

Volunteers who wish to participate in the study will be informed about the procedures of the study. Volunteers who agree to participate will sign the informed consent form.

Participants from Group 1 and Group 2 will visit nutritional intervention unit at Clinical Investigation Day 1 (day 1) and at Clinical Investigation Day 2 (day 8).

Participants from Group 3 and Group 4 will visit nutritional intervention unit after surgery for tumor removal, at Clinical Investigation Day 1 (day 1), at Clinical Investigation Day 2 (day 8), at Clinical Investigation Day 3 (1 year) and at Clinical Investigation Day 4 (1 year + day 8).

* Clinical Investigation Day 1 and 3: anthropometric and body composition measurements, delivery of questionnaires , blood extraction, placement of accelerometer . * Clinical Investigation Day 2 and 4: reception of accelerometer and collection of completed questionnaires.

Вмешательства

Другое Observational study (baseline)
Data will be collected at a single time point.
Другое Observational study (baseline and 1 year)
Data will be collected at two time points during the study period.

Первичные конечные точки

Lipid mediators profile [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3]

Вторичные конечные точки (12)

Body weight [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Height [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Body mass index [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Hip circumference [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Waist circumference [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Leg circumference [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Appendicular Skeletal Muscle Mass [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Fat mass percentage [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Fat mass (g) [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Lean mass [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Fat-free mass [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]
Visceral adipose tissue [Срок оценки: Clinical Investigation Day 1 and Clinical Investigation Day 3.]

Критерии участия

HEALTHY PARTICIPANTS:

Критерии включения

Postmenopause (al least 1 year).
Normoweight or overweight/obesity.
No personal history of cancer.
Stable weight over the last 3 months (±5%).
Willing to sign the informed consent and comply with all study procedures.

Критерии исключения

Personal history of cancer.
Current weight loss treatment (diet, supplementation, surgery, others...).
Bariatric surgery.
No stable pharmacological treatment for at least 3 months.
Diabetes treatment and hormone replacement therapy.
Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.
High alcohol intake, more than 14 units per week for women and 20 units per week for men.
Surgical interventions resulting in permanent sequelae of the gastrointestinal tract.
Liver disease, except for non-alcoholic fatty liver disease.
Cognitive and/or psychiatric impairment.
Poor compliance or difficulty following study procedures.

BREAST CANCER PARTICIPANTS:

Критерии включения

Postmenopause (at least 1 year).
Normoweight or overweight/obesity.
Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment.
Willing to sign the informed consent and comply with all study procedures.